MarketPulse

CELLECTRA device

14 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Inovio Investors Face April 7 Deadline in Securities Class Action Over Alleged Misstatements

Rosen Law Firm alerts $INO investors of April 7, 2026 deadline to join class action over alleged false statements regarding manufacturing and regulatory prospects.
INOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Pomerantz Files Securities Fraud Suit Against $INO Over FDA Approval Misstatements

Pomerantz LLP sues Inovio Pharmaceuticals for alleged securities fraud over FDA approval misstatements. Stock fell 3.1% and 24.45% following manufacturing delays and accelerated approval rejection.
INOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Inovio Faces Securities Class Action Over Vaccine Device Defects, Regulatory Claims

Rosen Law Firm seeks lead plaintiffs in securities class action against Inovio Pharmaceuticals for alleged misstatements on device defects, regulatory prospects, and product timelines. Lead plaintiff deadline: April 7, 2026.
INOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Inovio Faces Securities Fraud Class Action Over Manufacturing Claims and FDA Setbacks

Pomerantz Law Firm files class action against $INO for alleged securities fraud involving false manufacturing capability and FDA approval claims for INO-3107.
INOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Inovio Faces Securities Class Action Over Device Defects, Missed Regulatory Timelines

Rosen Law Firm files securities class action against Inovio Pharmaceuticals ($INO) alleging misleading statements on manufacturing deficiencies and overstated regulatory prospects. Lead plaintiff deadline April 7, 2026.
INOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Inovio Faces Class Action Over Alleged Misstatements on Device Manufacturing and FDA Timeline

Class action lawsuit filed against Inovio Pharmaceuticals for allegedly making false statements about CELLECTRA device manufacturing and INO-3107 FDA submission timeline between October 2023 and December 2025.
INOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Inovio Faces Securities Lawsuit Over Manufacturing Claims and Regulatory Missteps

Rosen Law Firm urges $INO investors to join class action lawsuit alleging false statements about manufacturing deficiencies and regulatory prospects.
INOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Schall Law Firm

Inovio Faces Securities Fraud Lawsuit Over Manufacturing Claims and BLA Delays

Schall Law Firm files securities fraud class action against $INO for allegedly making false statements about manufacturing deficiencies and regulatory filing timelines.
INOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Inovio Investors Urged to File Claims Before April Deadline in Securities Litigation

Rosen Law Firm notifies Inovio investors of securities class action with April 7, 2026 lead plaintiff deadline, citing alleged false statements on manufacturing and regulatory matters.
INOinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Inovio Pharmaceuticals Faces Class Action Over FDA Rejection and Device Claims

Inovio Pharmaceuticals faces class action lawsuit over alleged false statements regarding manufacturing defects and regulatory prospects after FDA rejected accelerated approval, causing 24% stock decline.
INOclass action lawsuitstock decline
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Lawsuit Filed Against Inovio Over Alleged Misstatements on Device Manufacturing and Regulatory Plans

Class action lawsuit filed against Inovio Pharmaceuticals for allegedly making false statements about device manufacturing capabilities and regulatory timelines between October 2023 and December 2025.
INOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Schall Law Firm Opens Class Action Against Inovio Over Manufacturing Claims

Schall Law Firm launches class action against Inovio Pharmaceuticals for alleged misrepresentations about manufacturing capabilities and regulatory timelines. Investors can join until April 7, 2026.
INOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Rosen Law Firm Files Securities Class Action Against Inovio Pharmaceuticals

Rosen Law Firm files securities class action against Inovio Pharmaceuticals for allegedly making false statements about manufacturing deficiencies and regulatory prospects between October 2023 and December 2025.
INOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Inovio Pharmaceuticals Faces Class Action Over Device Manufacturing Disclosures

Inovio Pharmaceuticals faces class action lawsuit for allegedly misleading investors about device manufacturing capabilities and regulatory delays, leading to 24% stock decline.
INOsecurities fraudclass action lawsuit